CDK4 and cancer: From January 2017 to October 2020, 456 patients who were diagnosed with hormone receptor‐positive, HER2‐negative ABC and treated with a CDK4/6i in combination with an aromatase inhibitor at the Yonsei Cancer Center were enrolled in this study (CONSORT diagram, Figure S1).